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Abstract
 
Chemokines are implicated in tumor pathogenesis, although it is unclear whether they affect
human cancer progression positively or negatively. We found that activation of the chemokine
receptor CCR5 regulates p53 transcriptional activity in breast cancer cells through pertussis
toxin–, JAK2-, and p38 mitogen–activated protein kinase–dependent mechanisms. CCR5
blockade significantly enhanced proliferation of xenografts from tumor cells bearing wild-type
p53, but did not affect proliferation of tumor xenografts bearing a p53 mutation. In parallel,
data obtained in a primary breast cancer clinical series showed that disease-free survival was
shorter in individuals bearing the CCR5
 
 
 
32 allele than in CCR5 wild-type patients, but only
for those whose tumors expressed wild-type p53. These findings suggest that CCR5 activity
influences human breast cancer progression in a p53-dependent manner.
Key words: chemokine receptor • breast cancer • p53 • CCR5 polymorphism • p38
 
Introduction
 
Many cancers express an extensive network of chemo-
kines and chemokine receptors (1, 2). Studies in animal
models suggest that chemokines may act on tumor cells
and/or tumor-infiltrating leukocytes (3–6). Tumor-pro-
duced chemokines are thought to have distinct roles in
the biology of primary and metastatic disease, including
(a) directing leukocyte infiltration into the tumor, (b) reg-
ulating the antitumor immune response, (c) controlling
tumor angiogenesis, (d) functioning as autocrine or para-
crine growth and survival factors, and (e) controlling tumor
cell movement.
Current evidence does not establish whether these che-
mokine biological activities in the tumor microenviron-
ment contribute to cancer growth and spread, or to host
antitumor response and cancer regression. Studies using the
CC chemokine CCL5 (RANTES) as a model reported that
elevated CCL5 levels in the tumor environment contribute
to improving the immune response against breast carcino-
mas (7), but also correlate with poor prognosis in breast can-
cers (8, 9). CCL5 also has a role in the chemotaxis and me-
tastasis of breast cancer cell lines (10–12). Selected cell lines
with an enhanced chemotactic response to CCL5 neverthe-
less showed decreased growth potential in nude mice, sug-
gesting an inverse correlation between CCL5-induced
chemotactic and proliferation signals (12). Compatible with
this, basic fibroblast growth factor–induced proliferation of
endothelial cells was inhibited by distinct chemokines, in-
cluding CCL5, via a noncompetitive mechanism (13).
These results indicate that the role of chemokines in tumor
progression is complex and poorly understood.
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 BrdU, bromodeoxyuridine; DFS, disease-
free survival; MAPK, mitogen-activated protein kinase; siRNA, small
interfering RNA.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
CCR5 Influences Breast Cancer Progression
 
1382
 
Here we studied the role of CCR5 in breast tumor pro-
gression by analyzing proliferation of xenografts derived
from tumor cells expressing wild-type or mutated p53 in
combination with wild-type or mutated CCR5. We also
took advantage of the fact that 
 
 
 
1% of the Caucasian pop-
ulation is homozygous for the CCR5
 
 
 
32 polymorphism,
which renders a nonfunctional CCR5 receptor, to study
the effect of this mutation in a clinical series of breast can-
cer patients. We describe a new mechanism by which
CCR5 influences human breast cancer progression, de-
pending on the status of the p53 tumor suppressor.
 
Materials and Methods
 
Cell Lines and Stimulation.
 
MCF-7 and MDA-MB-231 cells
(American Type Culture Collection) were transduced with retro-
viral pLZ-KDEL
 
 
 
32-IRES-gfp or pLZ-IRES-gfp (mock) super-
natants, and green fluorescent protein–expressing cells were se-
lected by fluorescence-activated cell sorting (11). The percentage
of CCR5
 
  
 
cells observed after subtracting the control value was
multiplied by average fluorescence intensity to calculate surface
CCR5 expression in mock and KDEL
 
 
 
32-expressing cells (14).
MCF-7-p53
 
175H 
 
cells were obtained by transfection with pWZL-
Hygro-p53
 
175H 
 
(provided by M. Serrano, Centro Nacional de
Biotechnologia, Madrid, Spain; reference 15), followed by hy-
gromycin selection. p53 silencing by small interfering RNA
(siRNA) was performed by transfecting MCF-7 cells with a pool
of p53-specific siRNA (SMARTpool kit; Dharmacon) at 100
nM using Oligofectamine (GIBCO BRL). Transfection effi-
ciency was 75 
 
  
 
5.1% as estimated using a fluorescent-labeled
siRNA. As a control, MCF-7 cells were transfected with nonspe-
cific pooled siRNA duplexes (Dharmacon). Finally, MCF-7 cells
were transfected with Flag-tagged dominant negative mutants for
MAP kinase kinases 3 and 6 (dnMKK3 and dnMKK6; provided
by R.J. Davis, Howard Hughes Medical Institute, University of
Massachusetts, Worcester, MA).
Serum-depleted mock, KDEL
 
 
 
32-, p53
 
175H
 
-, siRNA-,
dnMKK3-, dnMKK6-, or dnMKK3 plus dnMKK6–expressing
MCF-7 cells were stimulated with 100 nM CCL5 (PeproTech),
 
  
 
irradiated (30 Gy) or UV irradiated with UVC (254 nm, 30
J/m
 
2
 
), and then incubated at 37
 
 
 
C for the times indicated. Equal
protein amounts from cell lysates prepared with RIPA buffer (50
mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% SDS, 0.5% deoxy-
cholate, 1% NP-40) were analyzed by Western blot with anti-
p53 (Oncogene Research Products), anti-p21 and anti-Mdm2
(Santa Cruz Biotechnology, Inc.), anti-p38 and anti–phospho-
p38 mitogen-activated protein kinase (MAPK; no. 9211; New
England BioLabs, Inc.), and anti-Flag (Sigma-Aldrich) antibodies.
Protein loading was confirmed with anti-tubulin antibody
(Sigma-Aldrich). For some experiments, cells were pretreated for
14 h with 100 
 
 
 
M tyrphostin AG 490, 10 
 
 
 
M LY 294002, 10
 
 
 
M PD 98059, 10 
 
 
 
M SB 203580 (all from Calbiochem), 0.75
 
 
 
g/ml pertussis toxin (Sigma-Aldrich), or DMSO before CCL5
stimulation. Densitometric analysis of Western blots was per-
formed with NIH Image software.
 
Breast Tumor Xenograft Models and Immunohistochemistry.
 
Eight
female BALB/c-SCID mice were injected subcutaneously in
both flanks with 3 
 
  
 
10
 
6 
 
mock or KDEL
 
 
 
32-expressing MDA-
MB-231 or 5 
 
  
 
10
 
6 
 
MCF-7 cells. In the case of MCF-7, mice
were pretreated with 1 
 
 
 
g/ml 17
 
 
 
-ethynyl estradiol (Sigma-
Aldrich) in drinking water for 1 wk before cell injection and during
the experimental period. 4 wk after cell injection, mice received
 
two intraperitoneal injections of bromodeoxyuridine (BrdU; 10
mg/ml, 50 
 
 
 
l/mouse) 6 h apart, and primary tumors were re-
moved 4 h after the last injection. Some tumors were fixed in
70% ethanol, paraffin embedded, and analyzed for BrdU incorpo-
ration using anti-BrdU antibody (Becton Dickinson) or active
p38 MAPK using anti–phospho-p38 antibody (no. 9216; New
England BioLabs, Inc.). Other tumors were snap frozen in Tissue
Freezing Medium (Sakura Finetek) and cryosections were used
for in situ apoptosis determination by the TUNEL method
(MEBSTAIN Apoptosis kit II; Immunotech) or p21 detection.
Finally, some tumors were mechanically disrupted. Cell lysates
were prepared with RIPA buffer and used both to measure hu-
man CCL5 (Cytoscreen; Biosource International) and for p53,
p21, and Mdm2 analysis in Western blot. CCL5 levels, BrdU in-
corporation, and TUNEL data were compared using the two-
tailed Mann-Whitney test.
 
 
 
32 Genotyping of the Breast Cancer Cohort.
 
The breast can-
cer cohort comprised primary (nonmetastatic) breast cancer pa-
tients diagnosed at the Hospital Universitario 12 de Octubre,
Madrid, Spain, from January 1992 to December 1995. Stage IV
patients at diagnosis were excluded from this series. DNA was
isolated from biopsies of 547 patients and the CCR5
 
 
 
32 allele
determined with an automated method based on real-time PCR
in a Lightcycler system (16). Patients included in this study were
disease free after surgery and showed no initial metastases or me-
tastases within 3 mo after surgery.
Chemotherapy was administered to premenopausal patients
with tumors larger than 1 cm, postmenopausal patients with neg-
ative estrogen receptor expression, and patients showing affected
lymph nodes. Patients with conservative surgery and those show-
ing four or more axillary lymph nodes affected were treated with
radiotherapy. Patients whose tumors expressed hormone recep-
tors were treated with tamoxifen for 5 yr. Clinical follow-up was
performed according to institutional protocols by physical exami-
nation every 3 mo in the first 2 yr after surgery, every 6 mo in the
next 3 yr, and every year after the sixth year. Mammography was
performed yearly and other diagnostic tests were performed when
relapse was suspected. Disease-free survival (DFS) was defined as
the time (in months) from diagnosis of disease, usually coinciding
with surgery, to first relapse or to the last clinical revision for pa-
tients with no recurrence. A total of 133 out of 541 patients re-
lapsed (24.5%).
Allelic frequencies between patient groups where compared
using standard 
 
 
 
2 
 
tests with Yates correction, the Mantel-Haens-
zel test, or Fisher’s exact test where necessary, using Statcalc soft-
ware (EpiInfo 5.1). For statistical analysis of genotypes, 
 
 
 
32/
 
 
 
and 
 
 
 
32/
 
 
 
32 individuals were grouped to avoid values of 
 
 
 
7.
DFS was estimated using the Kaplan-Meier method and com-
pared by the log-rank test.
 
Online Supplemental Material.
 
Fig. S1 shows DFS curves in
breast cancer patients grouped according to CCR5 status. Fig.
S1 is available at http://www.jem.org/cgi/content/full/jem.
20030580/DC1.
 
Results
 
CCR5 Signaling Increases p53 Transcriptional Activity.
 
CCR5-mediated signals may regulate transcription of sev-
eral p53 target genes in certain cell types (17). To study the
association between CCR5 and p53 in cancer cells, we an-
alyzed CCR5-dependent signaling in the MCF-7 breast
carcinoma line, which expresses CCR5 and wild-type p53.T
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Stimulation of MCF-7 cells with CCL5, a ligand for
CCR5, increased levels of well-established p53-regulated
genes, such as p21
 
WAF1/CIP1 
 
and Mdm2 (Fig. 1 A). p53 pro-
tein levels were essentially unaltered after CCL5 stimula-
tion, although a slight increase was observed 60 min after
stimulation. To determine whether CCL5-mediated
p21
 
WAF1 
 
and Mdm2 up-regulation is dependent on p53
transcriptional activity, MCF-7 cells stably expressing a
dominant negative p53
 
175H 
 
mutant (15) were stimulated
with CCL5. CCL5 did not increase p21
 
WAF1 
 
or Mdm2
protein levels in MCF-7-p53
 
175H 
 
cells (Fig. 1 B). Concur-
rently, transfection of MCF-7 cells with p53-specific
siRNA prevented CCL5-induced p21
 
WAF1 
 
and Mdm2 up-
regulation (Fig. 1 C). As a control, p53-specific siRNA also
inhibited 
 
  
 
irradiation–induced up-regulation of p53 activ-
ity (Fig. 1 D). These results suggest that CCL5-induced
transcriptional activation of p53 target genes, such as
p21
 
WAF1 
 
and Mdm2, requires functional p53 protein.
To analyze whether CCL5-induced p53 activation re-
quires CCR5-mediated signaling at the cell surface, we spe-
cifically blocked CCR5 in MCF-7 cells with a CCR5
dominant negative mutant. We previously showed that
overexpression of a CCR5 deletion mutant (KDEL
 
 
 
32),
which is phenotypically similar to the natural CCR5
 
 
 
32
(
 
 
 
32) mutant, abrogates CCR5 function in MCF-7 cells
(11). This effect is probably due to a trans inhibitory effect
of the KDEL
 
 
 
32 mutant on CCR5 transport to the cell
surface (18). KDEL
 
 
 
32 expression reduced CCR5 levels by
 
 
 
70% (Fig. 1 E). CCL5 did not induce p21
 
WAF1 
 
or Mdm2
in KDEL
 
 
 
32-expressing MCF-7 cells (Fig. 1 F), indicating
that CCR5 is the specific receptor by which CCL5 induces
these genes. p21
 
WAF1 
 
and Mdm2 up-regulation were similar,
however, in mock- and KDEL
 
 
 
32-expressing MCF-7 cells
after 
 
  
 
irradiation, suggesting that KDEL
 
 
 
32 expression did
not affect the p53 pathway in these cells (Fig. 1 G).
 
p53 Transcriptional Activity Requires CCR5-mediated p38
Activation.
 
To study the mechanism by which CCR5 ac-
tivates p53, we used chemical inhibitors to block CCR5-
mediated signaling. Binding of chemokines to their recep-
tors leads to activation of heterotrimeric G proteins and
JAK family tyrosine kinases. These in turn initiate multiple
signaling cascades, including phosphatidylinositol-3 kinase
as well as p38 and p42/p44 MAPK pathways (19). Incuba-
tion of MCF-7 cells with the inhibitors LY 294002 and PD
98059, which block phosphatidylinositol-3 kinase and
p42/p44 MAPK pathways, has only a marginal effect on
CCR5 induction of p21
 
WAF1 
 
and Mdm2 (Fig. 2 A). In con-
trast, CCR5-mediated induction of p21
 
WAF1 
 
and Mdm2
was inhibited by treatment of MCF-7 cells with pertussis
toxin, AG 490, and SB 203580 (Fig. 2 A), which impede
G
 
i
 
, JAK-2, and p38 MAPK activation, respectively. In ad-
dition, CCL5 induced p38 phosphorylation in mock-trans-
fected MCF-7 cells, but not in KDEL
 
 
 
32-expressing cells
(Fig. 2 B), indicating that CCR5 mediates p38 MAPK acti-
Figure 1. CCR5 regulates p53 transcrip-
tional activity. (A) Time course induction of
p53 (dotted line,  ), p21WAF1 (solid line,  ),
and Mdm2 (dashed line,  ) in CCL5-stimulated
MCF-7 cells. Western blots from four indepen-
dent experiments were quantified by densitometry
and the values were normalized using the tubulin
loading control. Data points are plotted relative
to mean values obtained before chemokine addi-
tion (n   5). (B) CCL5-induced p53 targets in
MCF-7 cells expressing the p53175H  mutant.
One representative experiment of three is
shown. (C and D) MCF-7 cells transfected with
control or p53-specific siRNA oligonucleotides
were stimulated with CCL5 (C) and incubated
at 37 C for the times indicated or   irradiated
(30 Gy; D) and incubated for 3 h at 37 C. Cell
lysates were analyzed by Western blot. One
representative experiment of three is shown.
(E) CCR5 was detected in live mock- or
KDEL 32-expressing MCF-7 cells by FACS®.
Surface CCR5 expression in mock- and
KDEL 32-expressing cells was estimated by
multiplying average fluorescence intensity by
the percentage of CCR5  cells (n   3). (F and
G) Mock- and KDEL 32-expressing cells were
stimulated with CCL5 (F) or   irradiated (30
Gy; G) and incubated at 37 C for the times
indicated. Cell lysates were analyzed by Western
blot. One representative experiment of three is
shown.T
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vation. p38 phosphorylation was nonetheless similar in
mock and KDEL
 
 
 
32 cells after UV irradiation, indicating
that KDEL
 
 
 
32 expression does not affect p38 activation
per se (Fig. 2 C). Finally, we used dominant negative mu-
tants for MKK3 and MKK6 to block p38 MAPK activation
(20). Overexpression of dnMKK3 or dnMKK6 mutants
produced only modest inhibition of the CCL5-induced in-
crease in p21
 
WAF1 
 
and Mdm2 levels. Maximum inhibition
was observed when dnMKK3 and dnMKK6 were co-
expressed (Fig. 2 D). Likewise, UV-induced p38 phos-
phorylation was maximally inhibited in cells coexpressing
dnMKK3 and dnMKK6 (Fig. 2 E). The results suggest that
specific CCR5 activation at the cell surface enhances p53
transcriptional activity in MCF-7 breast cancer cells by a
G
 
i
 
-, JAK-, and p38-dependent mechanism(s).
 
The CCR5-p53 Pathway Regulates In Vivo Proliferation of
Human Breast Tumor Xenografts.
 
To study the CCR5-p53
pathway in tumor growth, we compared in vivo prolifera-
tion of mock- and KDEL
 
 
 
32-expressing MCF-7 (wild-
type p53) or MDA-MB-231 (mutated p53) cells implanted
into SCID mice. As for MCF-7, KDEL
 
 
 
32 mutant ex-
pression in MDA-MB-231 cells reduced surface CCR5
levels by 62 
 
  
 
4.2%. We measured the amount of human
CCL5 in extracts from mock and KDEL
 
 
 
32 xenografts
from both cell lines. CCL5 levels were comparable in
mock and KDEL
 
 
 
32 tumors (MCF-7-mock: 35.1 
 
  
 
7.5
pg/100 
 
 
 
g, 
 
n 
 
  
 
8; MCF-7-
 
 32: 41.7   10.6 pg/100  g,
n   8, P   0.5; MDA-MB-231-mock: 33.06   5.34 pg/
100  g, n   5; MDA-MB-231- 32: 50.21   17 pg/100
 g, n   7, P   0.15, Mann-Whitney test), suggesting that
all tumor types were equally exposed to CCL5.
BrdU incorporation experiments using the MCF-7 xe-
nografts showed that the percentage of BrdU  cells was
significantly higher in KDEL 32 than in mock tumors
(Fig. 3 A; P   0.05, Mann-Whitney test). It should be
noted, however, that subcutaneous MCF-7 xenograft im-
plantation and growth is dependent on estradiol supple-
mentation during the experimentation period, and that
estradiol induces equal proliferation of mock and KDEL 32-
expressing cells in vitro (unpublished data). This may at-
tenuate the differences observed in BrdU incorporation
between mock- and KDEL 32-expressing MCF-7 xe-
nografts. Similar BrdU chase experiments using MDA-
MB-231 tumors showed no BrdU incorporation differ-
ences when mock- and KDEL 32-expressing xenografts
were compared (Fig. 3 B). TUNEL assays of the xenografts
showed a comparable percentage of apoptotic cells in
mock and KDEL 32 derived from MCF-7 (Fig. 3 C) or
MDA-MB-231 (Fig. 3 D) tumors, indicating that CCR5
expression did not affect apoptosis.
p21WAF1 levels were increased in mock- compared with
KDEL 32-expressing MCF-7 xenografts (Fig. 4 A). Again,
KDEL 32 overexpression in MDA-MB-231 cells produced
no differences in p21WAF1 levels (Fig. 4 B). In agreement,
nuclear localization of p21WAF1 was clearly increased in mock
compared with KDEL 32-MCF-7 xenografts, but not in
those derived from MDA-MB-231 cells (Fig. 4 C). Collec-
tively, these data indicate that a reduction in functional cell
surface CCR5 may increase the proliferation rate of tumor
cells bearing wild-type p53, probably by diminishing levels
of the CDK inhibitor p21WAF1. To analyze whether p38
Figure 2. CCR5 regulates p53 activity through in a Gi-, JAK2-, and
p38 MAPK–dependent manner. (A) Measurement of p21WAF1 and Mdm2
induction analyzed by Western blot after CCL5 stimulation of MCF-7
cells pretreated with the indicated chemical inhibitors. Data points represent
the mean   SD of densitometric values obtained in two independent
experiments for each inhibitor. Data are plotted relative to those obtained
in DMSO-treated cells before CCL5 addition. (B and C) Mock- and
KDEL 32-expressing cells were stimulated with CCL5 (B) or UV irradi-
ated (30 J/m2, C), and then incubated at 37 C for the times indicated (for
CCL5) or for 30 min (for UV irradiation). Cell lysates were analyzed by
Western blot with anti–phospho-p38 (pp38) or anti-p38–specific anti-
bodies. One representative experiment of three is shown. (D and E)
Mock-, dnMKK3-, and dnMKK6-expressing cells and cells coexpressing
dnMKK3 and dnMKK6 were stimulated with CCL5 (D) or UV irradi-
ated (30 J/m2, E), and then incubated at 37 C as above. CCL5-induced
p21WAF1 mdm2 up-regulation was visualized by Western blot (D). In the
case of UV irradiation (E), cell lysates were analyzed by Western blot
with anti–phospho-p38 (pp38) or anti-p38–specific antibodies. In all
cases, dnMKK3 and dnMKK6 expression was detected using an anti-Flag
antibody. One representative experiment of two is shown.T
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MAPK was involved in this pathway, we stained mock and
KDEL 32-MCF-7 xenograft sections with an antibody
against the active form of p38 MAPK. Mock-derived xe-
nografts showed greater cytoplasmic and nuclear anti–phos-
pho-p38 staining than those derived from KDEL 32-MCF-7
(percent nuclei stained for phospho-p38: mock 13.67  
3.1%, KDEL 32 5.44   1.9%; Fig. 4 D). Thus, the results
suggest that the CCR5-p53 pathway is operative and regu-
lates in vivo breast cancer cell proliferation.
The CCR5-p53 Pathway Influences Human Breast Cancer
Progression. Chemokine and/or chemokine receptor
polymorphisms in the human population represent a
unique model by which to study the contribution of spe-
cific chemokines to pathogenesis.  32 is a 32-bp deletion
within the CCR5 coding region, which results in a frame
shift that generates a nonfunctional receptor (21–23). Ho-
mozygotes for this mutation ( 32/ 32) do not express
CCR5 on the cell surface, and receptor levels are also
greatly reduced in  32 heterozygotes ( 32/ ). Both  32/
 32 and  32/  individuals appear healthy and show no
apparent phenotype. Nonetheless, mutant  32 allele ex-
pression is associated with (a) resistance to HIV-1 infection
in homozygotes and slow progression to AIDS in heterozy-
gotes (21–23), (b) decreased severity of rheumatoid arthritis
(24–26) and (c) multiple sclerosis (27), (d) long-term sur-
vival of renal transplants (28), and (e) reduced risk of myo-
cardial infarction (29). These observations suggest a func-
tional role for CCR5 in these pathogenic processes.
To analyze the relevance of CCR5 in human breast can-
cer, we determined the allelic frequency and genotypes of
 32 polymorphism in 547 patients diagnosed of primary
(nonmetastatic) breast cancer. The median follow-up period
was 83 mo. Six patients were  32/ 32 and 74 were  32/ .
The allelic frequency of  32 in the cohort was 7.86%
(86 of 1,094 chromosomes). No differences were detected
in allelic frequencies between breast cancer patients and the
general population (P   0.97,  2 with Yates correction; ref-
erence 16). In addition, the genotype distribution observed
in breast cancer patients was in accordance with the Hardy-
Weinberg equilibrium law ( 2   0.57, P   0.75 with two
degrees of freedom). These data suggest that the  32 allele
is not associated with susceptibility to breast cancer.
We next explored the role of the  32 allele in breast
cancer by evaluating allelic frequency and genotypes of this
marker in patients grouped according to clinical, patholog-
ical, or molecular parameters (Table I). We found no bias
in  32 frequency when tumors were grouped according to
hormone receptor (estrogen or progesterone), ErbB-2, or
angiogenin expression. Significant differences in allele fre-
quencies between groups were observed, however, when
classified by tumor size. Specifically, patients with the larg-
est tumor size (T4) had a  32 allelic frequency of 14.3%, a
significant increase compared with the expected frequency
for this mutation in the cohort ( 2   4.07, P   0.043).
We analyzed whether the CCR5-induced p53 activation
observed in breast cancer cell lines influenced breast cancer
progression in humans. A larger proportion of tumors de-
rived from  32 patients tended to be negative for p53 ex-
pression than those derived from CCR5 wild-type individu-
als (Table I). Absence of aberrant p53 expression, which
usually corresponds to p53 mutation and is associated with
better prognosis in breast cancer (30), is considered an indica-
tion that this tumor suppressor gene is not mutated in these
cancers. We analyzed DFS in the cohort, sorted according to
p53 and CCR5 status. Because of the small number of ho-
mozygous patients,  32/ 32 and  32/  individuals were
grouped together. DFS differed significantly between  32
and wild-type CCR5 patients only in those individuals with
tumors with wild-type p53 (i.e., p53  tumors; Fig. 5, bot-
tom; P   0.021, log-rank test). DFS was comparable be-
tween  32 and wild-type CCR5 patients whose tumors ex-
pressed a mutated p53 form (i.e., p53  tumors; Fig. 5,
bottom; P    0.752, log-rank test). When samples were
grouped according to CCR5 status (Fig. S1, available at
Figure 3. Cell surface levels of
CCR5 specifically affect the pro-
liferation of breast tumor xe-
nografts with functional p53.
BrdU (A and B) and TUNEL (C
and D) staining of mock- and
KDEL 32-expressing MCF-7
(A and C) or MDA-MB-231 (B
and D) xenografts. Counterstaining
was done with hematoxylin and
eosin for BrdU and nuclei were
DAPI stained for TUNEL.  40.
Data points at the right represent
the percentage of BrdU   or
TUNEL  nuclei determined in
four random fields for each tumor
analyzed (two-tailed Mann-
Whitney test). *, P   0.05.T
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ence in DFS between the p53-mutated versus the wild-type
groups in  32 patients (P   0.68, log-rank test).
Discussion
Here we present genetic evidence for the role of the
CCR5 chemokine receptor in human breast cancer pro-
gression. First, we show that stimulation of a human breast
adenocarcinoma cell line with the chemokine CCL5 results
in activation of the tumor suppressor p53 through a mech-
anism that depends on specific cell surface CCR5 expres-
sion and Gi, JAK2, and p38-MAPK activation. Second, us-
ing a mouse xenograft model, we show that the link
Figure 4. p21WAF1 and phospho-p38-MAPK detection in xenografts
from mock- and KDEL 32-expressing tumor cells. (A and B) Lysates
from mock- and KDEL 32-expressing MCF-7 (A) or MDA-MB-231
(B) xenografts were analyzed sequentially with anti-p21WAF1, anti-Mdm2,
anti-p53, and anti-tubulin antibodies by Western blot. (C) Cryosections
of xenografts derived from mock- and KDEL 32-expressing MCF-7 and
MDA-MB-231 cells, as indicated, were stained with anti-p21WAF1 anti-
body followed by a peroxidase-labeled second antibody. Counterstaining
was performed with hematoxylin and eosin. (D) Paraffin sections from
mock- and KDEL 32-expressing MCF-7 xenografts were stained with
an anti–phospho-p38 antibody followed by a peroxidase-labeled second
antibody, and were hematoxylin and eosin counterstained. For C and D,
the background staining with the second antibody was also analyzed (not
depicted).  40.
Table I. Clinical Characteristics of Breast Cancer Patients 
(n   547)
Allele frequency
Clinical parameter CCR5wt CCR5 32 P ( 2)
Age  50 91.35 8.65 0.59
 50 92.46 7.53
Menopausal status Pre-Peri 92.72 7.28 0.73
Post 91.96 8.04
Histologic grade I-II 91.64 8.36 0.86
III 91.07 8.93
Tumor size T1 92.82 7.18
T2 92.44 7.56
T3 92.04 7.95
T4 85.71 14.29 0.04
Lymph node infiltration 0 92.41 7.58
1–3 93.08 6.91
4–9 92.96 7.04
 10 89.58 10.4 0.36
Stage I 92.02 7.97
II 92.62 7.38
III 89.24 10.76 0.22
Estrogen receptor Neg 91.21 8.79 0.52
Pos 92.54 7.46
Progesterone receptor Neg 91.63 8.37 0.76
Pos 92.32 7.68
ErbB-2 Neg 92.87 7.13 0.62
Pos 91.48 8.52
Angiogenin Neg 94.11 5.88 0.63
Pos 92.21 7.79
p53 Neg 91.11 8.89
Pos 94.11 5.89 0.1
Estrogen receptor  defined as  10 fmol/mg, progesterone receptor 
as   20 fmol/mg (Abbott), ErbB-2  as   15 HNU/ g (Oncogene
Science), angiogenin  as  5 ng/mg (R&D Systems), and p53  defined
by Western blot with pAb 181 (Oncogene Science) according to
established standards.
http://www.jem.org/cgi/content/full/jem.20030580/DC1),
it was found that those wild-type CCR5 patients whose tu-
mors had wild-type p53 showed a better prognosis than
those with mutant p53 (P   0.0051, log-rank test), concur-
ring with the previously reported prognostic value of p53
(30). In contrast, there was no statistically significant differ-T
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between CCR5 and p53 is operative in regulating in vivo
proliferation of tumor cells. Abrogation of cell surface
CCR5 expression enhanced proliferation of tumor cells
bearing wild-type p53, but not of tumor cell lines express-
ing a mutated p53 form. Finally, based on the CCR5 32
polymorphism in humans, which renders a nonfunctional
CCR5 receptor, we found that CCR5 status influenced
disease progression in a genotyped cohort of 547 patients
diagnosed with primary (nonmetastatic) breast cancer. We
found that DFS was shorter in CCR5 32 than in CCR5
wild-type patients with wild-type p53 tumors. Conversely,
DFS was comparable between CCR5 32 and CCR5
wild-type patients whose tumors had mutant p53.
Our results suggest a negative correlation between
CCR5 expression and the growth of human breast tumors
expressing wild-type p53. As seen in our tumor xenograft
models, CCL5 production in the tumor environment does
not increase apoptosis, but restricts growth of cancer cells
expressing wild-type p53 in a CCR5-dependent manner.
These results concur with previous data showing the ability
of CCL5 to inhibit growth factor–induced cell prolifera-
tion (13), as well as CCL5-induced stabilization of p53 in
neuronal and astrocytic nuclei (17). In some cases, CCL5
can also activate the apoptotic pathway in CCR5-express-
ing cells (31). How CCR5 transmits the signal to p53 re-
quires future investigation, but the data presented here sug-
gest a role for p38 MAPK in this pathway. In agreement
with others (32, 33), we found that CCL5-induced p38 ac-
tivation at the cell surface was CCR5 expression depen-
dent. Moreover, the active p38 MAPK form stained more
intensely in mock-derived xenografts than in those derived
from cells expressing the KDEL 32 mutant, indicating that
the CCR5-p38 MAPK pathway probably operates in this
in vivo model. Because p38 MAPK is a prominent p53 ac-
tivator in response to stress signals and certain anti-cancer
drugs (34, 35), CCR5-induced p38 phosphorylation can
activate p53 transcriptional activity, leading to p21WAF1 in-
duction and slowing of tumor cell growth.
Concurring with this hypothesis, the data from our co-
hort suggest that CCR5 influences the p53 mutation rate in
human tumors. The p53 tumor suppressor gene is inacti-
vated by mutation in approximately half of all human tu-
mors. Evidence suggests that tumor cells have developed
mechanisms other than mutation to “silence” p53 function
(36). We found that mutation of p53 affected 46% of tu-
mors from CCR5 wild-type individuals, but only 35% of
tumors from CCR5 32 patients. Moreover, no tumors
from the  32/ 32 patients showed mutant p53. These data
strongly suggest that there is less selective pressure for p53
mutation in tumors from CCR5 32 individuals than from
those bearing CCR5 wild-type alleles. In CCR5 32 pa-
tients, all pathways downstream of CCR5 are abolished
(homozygous) or severely impaired (heterozygous) and
CCR5-mediated p53 activation is consequently diminished.
It is thus possible that p53 would be silenced in CCR5 32
patients under conditions in which this tumor suppressor
gene is activated in CCR5 wild-type individuals.
In apparent contradiction to our results, elevated CCL5
levels are reported in patients with progressive breast cancer
(8, 9), although it is noteworthy that these studies provide
no information on CCR5 and p53 expression. In one of
these reports, markedly elevated plasma levels of CCL5
were found in 27% of patients with progressive cancer,
raising the possibility that the CCL5 mediates tumor pro-
gression in some patients but not in others (9). Indeed, in
our cohort, the  32 polymorphism affects only breast can-
cer progression in patients whose tumors expressed wild-
type p53.
CCR5 may also have an indirect effect on cancer pro-
gression by controlling the antitumor immune response.
CCR5 participates in chemotaxis of memory and activated
naive T cells and is required for T cell activation (37). Ele-
Figure 5. The  32 polymorphism affects human breast cancer progression.
Kaplan-Meier DFS curves for the 547 breast cancer patients evaluated
according to p53 expression and the  32 polymorphism, as indicated.
CCR5 wild-type ( / ) patients, solid line;  32/  and  32/ 32 patients,
dashed line.
Table II. Lymphocyte Infiltration in Breast Tumors
Infiltration grade      32/   32/ 32
  52 4
   11 0
    10 0
Lymphocyte infiltration  50% ( ), equal to 50% (  ), or  50%
(   ) per field at low magnification ( 10).T
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vated lymphocyte infiltration is a rare event in breast can-
cer, as confirmed by analysis of lymphocyte infiltration in
14 random samples from the cohort (Table II). Although
additional research is needed to clarify the relevance of  32
polymorphism in the antitumor immune response, it is
noteworthy that DFS curves in our cohort were similar be-
tween  32 and wild-type patients whose tumors expressed
mutant p53. This suggests that the CCR5-dependent anti-
tumor immune response does not have a major impact on
this cancer progression. Alternatively, immune system im-
pairment in  32 patients may only be important in those
tumors with a benign prognosis (wild-type p53 tumors).
In summary, we have identified a Gi-, JAK2-, and p38-
dependent pathway by which CCR5 regulates p53 tran-
scriptional activity. This pathway appears to be silenced or
severely impaired in individuals bearing the mutated
CCR5  32 allele. As a consequence, breast tumors with
wild-type p53 grow faster and relapse sooner in  32 carri-
ers than in wild-type CCR5 individuals. This connection
between CCR5 and the tumor suppressor p53 represents a
previously unknown mechanism controlling human tumor
progression and provides a rationale for new approaches to
cancer treatment using CCL5.
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